Olokizumab, another IL-6 Inhibitor for RA This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets interleukin-6 (IL-6) in patients with rheumatoid arthritis (RA). https://t.co/VMz8xzffiZ https://t.co/eaA4CUWvrv